High-Level Investor Deck for Innovative Drug

This presentation explores NutriPart-B™, a groundbreaking solution targeting metabolic dysfunction through PPAR-δ and AMPK activation with innovative adipocyte-focused and liposomal delivery mechanisms. It discusses its clinical efficacy and safety, highlighting advantages over existing therapies and avoidance of common side effects. Market opportunities emphasize its potential in the $100B obesity sector, with standalone or combination use, alongside compelling investment rationale and...